头孢他啶-阿维巴坦及对照药物对在克罗地亚、捷克共和国、匈牙利、波兰、拉脱维亚和立陶宛收集的铜绿假单胞菌和肠杆菌科细菌的抗菌活性：2019年ATLAS监测项目
Antimicrobial activity of ceftazidime-avibactam and comparators against Pseudomonas aeruginosa and Enterobacterales collected in Croatia, Czech Republic, Hungary, Poland, Latvia and Lithuania: ATLAS Surveillance Program, 2019.
作者信息
Adámková V, Mareković I, Szabó J, Pojnar L, Billová S, Horvat Herceg S, Kuraieva A, Możejko-Pastewka B
机构信息
Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital, Prague, Czech Republic.
Department of Clinical and Molecular Microbiology, University Hospital Centre Zagreb, Zagreb, Croatia.
出版信息
Eur J Clin Microbiol Infect Dis. 2022 Jun;41(6):989-996. doi: 10.1007/s10096-022-04452-1. Epub 2022 May 20.
Abstract
Antimicrobial susceptibility of clinical isolates collected from sites in central Europe in 2019 was tested by CLSI broth microdilution method and EUCAST breakpoints. Most active were amikacin, ceftazidime-avibactam and colistin; respectively, susceptibility rates among P. aeruginosa (n = 701) were 89.2%, 92.2% and 99.9%; difficult-to-treat (DTR) isolates, 62.5%, 37.5% and 100%; multidrug-resistant (MDR) isolates, 68.3%, 72.9% and 99.5%; meropenem-resistant (MEM-R), metallo-β-lactamase-negative (MBL-negative) isolates, 72.8%, 78.6% and 100%. Among Enterobacterales (n = 1639), susceptibility to ceftazidime-avibactam, colistin and tigecycline was ≥ 97.9%; MDR Enterobacterales, 96.8%, 94.4% and 100%, respectively; DTR isolates, ≥ 76.2% to ceftazidime-avibactam and colistin; MEM-R, MBL-negative isolates, ≥ 90.0% to ceftazidime-avibactam and colistin.
摘要
采用美国临床和实验室标准协会（CLSI）肉汤微量稀释法及欧洲抗菌药物敏感性试验委员会（EUCAST）的断点值，对2019年从欧洲中部地区采集的临床分离株进行了药敏试验。最有效的药物是阿米卡星、头孢他啶-阿维巴坦和黏菌素；在铜绿假单胞菌（n = 701）中，药敏率分别为89.2%、92.2%和99.9%；难治性（DTR）分离株分别为62.5%、37.5%和100%；多重耐药（MDR）分离株分别为68.3%、72.9%和99.5%；耐美罗培南（MEM-R）、金属β-内酰胺酶阴性（MBL阴性）分离株分别为72.8%、78.6%和100%。在肠杆菌科细菌（n = 1639）中，对头孢他啶-阿维巴坦、黏菌素和替加环素的药敏率≥97.9%；MDR肠杆菌科细菌分别为96.8%、94.4%和100%；DTR分离株对头孢他啶-阿维巴坦和黏菌素的药敏率≥76.2%；MEM-R、MBL阴性分离株对头孢他啶-阿维巴坦和黏菌素的药敏率≥90.0%。
相似文献
1
Antimicrobial activity of ceftazidime-avibactam and comparators against Pseudomonas aeruginosa and Enterobacterales collected in Croatia, Czech Republic, Hungary, Poland, Latvia and Lithuania: ATLAS Surveillance Program, 2019.头孢他啶-阿维巴坦及对照药物对在克罗地亚、捷克共和国、匈牙利、波兰、拉脱维亚和立陶宛收集的铜绿假单胞菌和肠杆菌科细菌的抗菌活性：2019年ATLAS监测项目
Eur J Clin Microbiol Infect Dis. 2022 Jun;41(6):989-996. doi: 10.1007/s10096-022-04452-1. Epub 2022 May 20.
2
In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016-2018).临床呼吸道分离株对头孢他啶-阿维巴坦及对照药物的体外抗菌敏感性（2016 - 2018年）
BMC Infect Dis. 2021 Jun 23;21(1):600. doi: 10.1186/s12879-021-06153-0.
3
4
In vitro activity of ceftazidime-avibactam and comparators against Gram-negative bacterial isolates collected in the Asia-Pacific region as part of the INFORM program (2015-2017).亚太地区 INFORM 项目（2015-2017 年）收集的革兰氏阴性细菌分离株的头孢他啶-阿维巴坦和对照药物的体外活性。
Ann Clin Microbiol Antimicrob. 2020 Apr 1;19(1):14. doi: 10.1186/s12941-020-00355-1.
5
In vitro activity of ceftazidime-avibactam and comparators against Enterobacterales and Pseudomonas aeruginosa isolates from Central Europe and Israel, 2014-2017 and 2018.2014-2017 年和 2018 年中欧和以色列肠杆菌科和铜绿假单胞菌分离株的头孢他啶-阿维巴坦和对照药物的体外活性。
Diagn Microbiol Infect Dis. 2021 Sep;101(1):115420. doi: 10.1016/j.diagmicrobio.2021.115420. Epub 2021 May 7.
6
In vitro activity of ceftazidime-avibactam against Gram-negative isolates collected in 18 European countries, 2015-2017.2015-2017 年 18 个欧洲国家分离的革兰氏阴性菌对头孢他啶-阿维巴坦的体外活性。
Int J Antimicrob Agents. 2020 Sep;56(3):106045. doi: 10.1016/j.ijantimicag.2020.106045. Epub 2020 Jun 6.
7
In vitro activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa isolates collected in Latin America as part of the ATLAS global surveillance program, 2017-2019.2017-2019 年，在拉丁美洲参与 ATLAS 全球监测项目中收集的肠杆菌科和铜绿假单胞菌分离株的头孢他啶-阿维巴坦的体外活性。
Braz J Infect Dis. 2021 Nov-Dec;25(6):101647. doi: 10.1016/j.bjid.2021.101647. Epub 2021 Nov 10.
8
Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Asia-Pacific Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015.亚太地区国家收集的肠杆菌科和铜绿假单胞菌临床分离株中头孢他啶-阿维巴坦的活性：来自 INFORM 全球监测计划的结果，2012 年至 2015 年。
Antimicrob Agents Chemother. 2018 Jun 26;62(7). doi: 10.1128/AAC.02569-17. Print 2018 Jul.
9
In vitro activity of ceftazidime/avibactam and comparators against Gram-negative bacterial isolates collected from Latin American centres between 2015 and 2017.2015 年至 2017 年间拉丁美洲各中心分离的革兰氏阴性细菌的头孢他啶/阿维巴坦及比较药物的体外活性。
J Antimicrob Chemother. 2020 Jul 1;75(7):1859-1873. doi: 10.1093/jac/dkaa089.
10
Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Latin American Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015.头孢他啶-阿维巴坦对拉丁美洲国家临床分离的肠杆菌科和铜绿假单胞菌的活性：来自 INFORM 全球监测计划的结果，2012 年至 2015 年。
Antimicrob Agents Chemother. 2019 Mar 27;63(4). doi: 10.1128/AAC.01814-18. Print 2019 Apr.
引用本文的文献
1
Global trends of ceftazidime-avibactam resistance in gram-negative bacteria: systematic review and meta-analysis.革兰氏阴性菌对头孢他啶-阿维巴坦耐药性的全球趋势：系统评价与荟萃分析
Antimicrob Resist Infect Control. 2025 Feb 11;14(1):10. doi: 10.1186/s13756-025-01518-5.
2
In vitro activity of antibiotics potentially effective against difficult-to-treat strains of Gram-negative rods: retrospective study.体外抗生素活性研究：针对难治疗革兰氏阴性菌菌株的潜在有效抗生素的回顾性研究。
Sci Rep. 2024 Apr 9;14(1):8310. doi: 10.1038/s41598-024-59036-0.
3
Microbiota Assessment of Pediatric Simple and Complex Acute Appendicitis.儿科单纯性和复杂性急性阑尾炎的微生物组评估。
Medicina (Kaunas). 2022 Aug 23;58(9):1144. doi: 10.3390/medicina58091144.
本文引用的文献
1
In vitro activity of ceftazidime-avibactam and comparators against Enterobacterales and Pseudomonas aeruginosa isolates from Central Europe and Israel, 2014-2017 and 2018.2014-2017 年和 2018 年中欧和以色列肠杆菌科和铜绿假单胞菌分离株的头孢他啶-阿维巴坦和对照药物的体外活性。
Diagn Microbiol Infect Dis. 2021 Sep;101(1):115420. doi: 10.1016/j.diagmicrobio.2021.115420. Epub 2021 May 7.
2
Antimicrobial Resistance in ESKAPE Pathogens.ESKAPE 病原体中的抗微生物药物耐药性。
Clin Microbiol Rev. 2020 May 13;33(3). doi: 10.1128/CMR.00181-19. Print 2020 Jun 17.
3
Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies.铜绿假单胞菌的抗生素耐药性：机制与替代治疗策略。
Biotechnol Adv. 2019 Jan-Feb;37(1):177-192. doi: 10.1016/j.biotechadv.2018.11.013. Epub 2018 Nov 27.
4
Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents.173 家美国医院革兰氏阴性菌菌血症的难治性耐药：所有一线药物耐药的患病率、预测因素和结局的回顾性队列分析。
Clin Infect Dis. 2018 Nov 28;67(12):1803-1814. doi: 10.1093/cid/ciy378.
5
In vitro activity of ceftazidime/avibactam against isolates of Pseudomonas aeruginosa collected in European countries: INFORM global surveillance 2012-15.在体外研究头孢他啶/阿维巴坦对欧洲国家收集的铜绿假单胞菌分离株的活性：INFORM 全球监测 2012-2015 年。
J Antimicrob Chemother. 2018 Oct 1;73(10):2777-2781. doi: 10.1093/jac/dky267.
6
In vitro activity of ceftazidime/avibactam against isolates of Enterobacteriaceae collected in European countries: INFORM global surveillance 2012-15.2012-2015 年欧洲国家分离的肠杆菌科细菌对头孢他啶/阿维巴坦的体外活性：INFORM 全球监测研究。
J Antimicrob Chemother. 2018 Oct 1;73(10):2782-2788. doi: 10.1093/jac/dky266.
7
Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial.头孢他啶-阿维巴坦与美罗培南治疗医院获得性肺炎，包括呼吸机相关性肺炎（REPROVE）：一项随机、双盲、III 期非劣效性试验。
Lancet Infect Dis. 2018 Mar;18(3):285-295. doi: 10.1016/S1473-3099(17)30747-8. Epub 2017 Dec 16.
8
Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program.头孢他啶-阿维巴坦与多利培南治疗复杂性尿路感染（包括急性肾盂肾炎）：RECAPTURE，一项3期随机试验项目。
Clin Infect Dis. 2016 Sep 15;63(6):754-762. doi: 10.1093/cid/ciw378. Epub 2016 Jun 16.
9
In Vitro Susceptibility of Global Surveillance Isolates of Pseudomonas aeruginosa to Ceftazidime-Avibactam (INFORM 2012 to 2014).全球监测分离的铜绿假单胞菌对头孢他啶-阿维巴坦的体外敏感性（2012年至2014年INFORM研究）
Antimicrob Agents Chemother. 2016 Jul 22;60(8):4743-9. doi: 10.1128/AAC.00220-16. Print 2016 Aug.
10
Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.头孢他啶-阿维巴坦或最佳现有治疗在头孢他啶耐药肠杆菌科和铜绿假单胞菌引起的复杂性尿路感染或复杂性腹腔内感染患者中的应用（REPRISE）：一项随机、针对病原体的 3 期研究。
Lancet Infect Dis. 2016 Jun;16(6):661-673. doi: 10.1016/S1473-3099(16)30004-4. Epub 2016 Apr 20.
Zotero 插件